Literature DB >> 30283731

Lessons learned from rindopepimut treatment in patients with EGFRvIII-expressing glioblastoma.

David C Binder1, Erik Ladomersky2, Alicia Lenzen2, Lijie Zhai2, Kristen L Lauing2, Sebastian D Otto-Meyer3, Rimas V Lukas4,5,6, Derek A Wainwright2,3,5,6,7.   

Abstract

Entities:  

Year:  2018        PMID： 30283731      PMCID： PMC6166880     

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN： 2218-676X            Impact factor:   1.241


× No keyword cloud information.
  13 in total

Review 1.  Building better monoclonal antibody-based therapeutics.

Authors:  George J Weiner
Journal:  Nat Rev Cancer       Date:  2015-06       Impact factor: 60.716

2.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Authors:  James Schuster; Rose K Lai; Lawrence D Recht; David A Reardon; Nina A Paleologos; Morris D Groves; Maciej M Mrugala; Randy Jensen; Joachim M Baehring; Andrew Sloan; Gary E Archer; Darell D Bigner; Scott Cruickshank; Jennifer A Green; Tibor Keler; Thomas A Davis; Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2015-01-13       Impact factor: 12.300

3.  Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.

Authors:  Michael Weller; Nicholas Butowski; David D Tran; Lawrence D Recht; Michael Lim; Hal Hirte; Lynn Ashby; Laszlo Mechtler; Samuel A Goldlust; Fabio Iwamoto; Jan Drappatz; Donald M O'Rourke; Mark Wong; Mark G Hamilton; Gaetano Finocchiaro; James Perry; Wolfgang Wick; Jennifer Green; Yi He; Christopher D Turner; Michael J Yellin; Tibor Keler; Thomas A Davis; Roger Stupp; John H Sampson
Journal:  Lancet Oncol       Date:  2017-08-23       Impact factor: 41.316

4.  Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

Authors:  Stephen J Schuster; Jakub Svoboda; Elise A Chong; Sunita D Nasta; Anthony R Mato; Özlem Anak; Jennifer L Brogdon; Iulian Pruteanu-Malinici; Vijay Bhoj; Daniel Landsburg; Mariusz Wasik; Bruce L Levine; Simon F Lacey; Jan J Melenhorst; David L Porter; Carl H June
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

5.  Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas.

Authors:  Martin J van den Bent; Ya Gao; Melissa Kerkhof; Johan M Kros; Thierry Gorlia; Kitty van Zwieten; Jory Prince; Sjoerd van Duinen; Peter A Sillevis Smitt; Martin Taphoorn; Pim J French
Journal:  Neuro Oncol       Date:  2015-02-16       Impact factor: 12.300

6.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.

Authors:  John H Sampson; Kenneth D Aldape; Gary E Archer; April Coan; Annick Desjardins; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

7.  Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors.

Authors:  Amy B Heimberger; Laura E Crotty; Gary E Archer; Kenneth R Hess; Carol J Wikstrand; Allan H Friedman; Henry S Friedman; Darell D Bigner; John H Sampson
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

8.  Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Authors:  Christopher E Pelloski; Karla V Ballman; Alfred F Furth; Li Zhang; E Lin; Erik P Sulman; Krishna Bhat; J Matthew McDonald; W K Alfred Yung; Howard Colman; Shiao Y Woo; Amy B Heimberger; Dima Suki; Michael D Prados; Susan M Chang; Fred G Barker; Jan C Buckner; C David James; Kenneth Aldape
Journal:  J Clin Oncol       Date:  2007-06-01       Impact factor: 44.544

9.  Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.

Authors:  Kristina Ellwanger; Uwe Reusch; Ivica Fucek; Stefan Knackmuss; Michael Weichel; Thorsten Gantke; Vera Molkenthin; Eugene A Zhukovsky; Michael Tesar; Martin Treder
Journal:  Front Oncol       Date:  2017-05-19       Impact factor: 6.244

Review 10.  Chimeric antigen receptor T cells: a novel therapy for solid tumors.

Authors:  Shengnan Yu; Anping Li; Qian Liu; Tengfei Li; Xun Yuan; Xinwei Han; Kongming Wu
Journal:  J Hematol Oncol       Date:  2017-03-29       Impact factor: 17.388
View more
  5 in total

1.  Multiepitope supramolecular peptide nanofibers eliciting coordinated humoral and cellular antitumor immune responses.

Authors:  Yaoying Wu; Hanning Wen; Zachary J Bernstein; Kelly M Hainline; Tykia S Blakney; Kendra L Congdon; David J Snyder; John H Sampson; Luis Sanchez-Perez; Joel H Collier
Journal:  Sci Adv       Date:  2022-07-20       Impact factor: 14.957

Review 2.  Immunotherapy in Glioblastoma: Current Approaches and Future Perspectives.

Authors:  Ugur Sener; Michael W Ruff; Jian L Campian
Journal:  Int J Mol Sci       Date:  2022-06-24       Impact factor: 6.208

Review 3.  EGFRvIII: An Oncogene with Ambiguous Role.

Authors:  Adrianna Rutkowska; Ewelina Stoczyńska-Fidelus; Karolina Janik; Aneta Włodarczyk; Piotr Rieske
Journal:  J Oncol       Date:  2019-12-16       Impact factor: 4.375

Review 4.  Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging.

Authors:  Deling Li; Chirag B Patel; Guofan Xu; Andrei Iagaru; Zhaohui Zhu; Liwei Zhang; Zhen Cheng
Journal:  Front Immunol       Date:  2020-10-30       Impact factor: 7.561

5.  EGFRvIII expression and isocitrate dehydrogenase mutations in patients with glioma.

Authors:  Mohiuddin M Taher; Ghida Dairi; Ejaz Muhammad Butt; Khalid Al-Quthami; Hisham Al-Khalidi; Raid A Jastania; Tahani H Nageeti; Neda M Bogari; Mohammad Athar; Faisal A Al-Allaf; Kristoffer Valerie
Journal:  Oncol Lett       Date:  2020-10-23       Impact factor: 2.967
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.